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C1-inhibitor (C1-INH) deficiency is a rare blood disorder resulting in angioedema attacks that are debilitating and
may be life-threatening. Prophylaxis and therapy of events has changed since our first Canadian Consensus Confer-
ence on the diagnosis, therapy and management of HAE. We have formed the Canadian Hereditary Angioe-
dema Network (CHAEN)/Réseau Canadien d’Angioédème Héréditaire (RCAH) - http://www.haecanada.com to
advance care of patients with this disorder in Canada. We here present a review of management of HAE in
Canada.
Introduction
C1 inhibitor (C1-INH) deficiency presents in congenital
(hereditary angioedema, HAE) or acquired forms. There
are three variants of hereditary angioedema (HAE):
HAE-C1-INH Type I with low C1-INH protein and
function (85% of cases; autosomal dominant); HAE-C1-
INH Type II with normal protein but low function (15%
of cases; autosomal dominant); and HAE Type III her-
editary angioedema with normal C1 inhibitor protein
and function (estrogen-dependent inherited form found
mostly in females; some with defects in coagulation fac-
tor XII, HAE-FXII; others of unknown defect, HAE-
Unknown) [1,2]. Acquired angioedema (AAE) is most
frequently associated with lymphoproliferative and auto-
immune disorders and with some medications including
ACE inhibitors and plasmin activators [3,4]. Patients
with HAE may experience recurrent soft tissue swel-
lings, intestinal swellings, and abdominal pains, and may
have life-threatening swellings of the airway. The inci-
dence of HAE is estimated at 1:10,000 to 1:50,000. Risk
of dying from airway obstruction is not clear but deaths
from this complication if left untreated are not uncom-
mon [1,5].
To learn from international experience in HAE, the
first C1-INH Deficiency Workshop was convened by the
Hungarian HAE Center in May 1999 and they have
organized ongoing workshops every two years. The 6
th
International C1-INH Deficiency Workshop was held in
May 2009 in Budapest http://www.haenet.hu/new/
index2.html.
In Canada, Jeanne Burnham organized the HAE
patient organization and Scientific Advisory Committee
interested in advancing the standard of care for HAE in
Canada and from this grew the Canadian Hereditary
Angioedema Society (CHAES)/Société d’angioédème
héréditaire du Canada (SAHC) established in 2001. This
group recently disbanded and evolved into an informal
network of HAE physicians with patient advisory input,
the Canadian Hereditary Angioedema Network
(CHAEN)/Réseau Canadien d’Angioédème Hérédi-
taire (RCAH) - http://www.haecanada.com. The first
meeting of CHAEN/RCAH took place together with the
Canadian Society of Allergy and Clinical Immunology/
La Société canadienne d’allergie et d’immunologie clini-
que (CSACI/SCAIC) in Edmonton, Alberta, Canada
September 2007 and its second meeting in Toronto,
Ontario, Canada May 16
th, 2010 along with the Cana-
dian HAE Consensus 2010 Conference http://www.hae-
canada.com/m.php?p=ehome. In 2002, we proposed to
coordinate therapy for HAE in Canada modeled after
the hemophilia experience in Canada [6]. CHAES/SAHC
organized an international HAE consensus meeting held
in Toronto, Ontario, Canada October 2003 and from
this came the first Canadian International Consensus for
the diagnosis, therapy, and management of HAE [7].
The 2003 Toronto HAE Consensus meeting was held
under the sponsorship of the Canadian Hematology
Society and was the first meeting of the Network of
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work-of-rare-blood-disorder-organizations/) for Canada,
and was updated in 2007 [1] through the NRBDO, the
6
th International C1-INH Deficiency Workshop and the
2010 Canadian HAE Consensus Conference being held
in Toronto, Ontario, Canada May 15
th and 16
th,2 0 1 0
sponsored by CHAEN/RCAH, the Canadian Society of
Allergy and Clinical Immunology, the University of Cal-
gary, and funded by an unrestricted educational grant
from CSL Behring http://www.haecanada.com/m.php?
p=ehome. The updated Canadian Consensus will be
submitted to the Journal: Allergy Asthma and Clinical
Immunology, the official Journal of the CSACI/SCAIC
[8]; http://www.aacijournal.com/.
Canadian Hereditary Angioedema Network (CHAEN)/
Réseau Canadien d’Angioédème Héréditaire (RCAH)
CHAEN/RCAH is an informal organization modeled
after the Association of Hemophilia Clinic Directors of
Canada http://www.ahcdc.ca/. Currently, the Chair is
Dr. Tom Bowen, University of Calgary http://tbowen@-
pol.net and the Vice-Chair Western Canada is Dr. Bruce
Ritchie, University of Alberta and the Vice-Chair East-
ern Canada is Dr. Jacques Hebert, Laval University. The
CHAEN/RCAH website is: http://www.haecanada.com/
and the CHAEN/RCAH Webmaster is John Brosz.
CHAEN/RCAH Clinic Directors collaborate with the
HAE International Medical Advisory Panel http://www.
haei.org/?q=node/290 and attempt to harmonize with
their global initiatives including data registry and pro-
motion of research. Our CHAEN/RCAH Clinic Direc-
tors Group and Patient Advisory Committee will work
to prevent duplication of activities, minimize overlap of
efforts, and work towards exchange of data base registry
data in an unlinked fashion with international groups
and push for open publication of treatment protocols.
CHAEN/RCAH tries to meet every two years (first
meeting was in conjunction with the Canadian Society
of Allergy and Clinical immunology, Edmonton, Sep-
tember 2007). We try to update the Canadian HAE
Consensus protocols, involve the CHAEN/RCAH
Patient Advisory Group, involve the CHAEN/RCAH
Clinic medical and paramedical staff, and foster research
in HAE management in Canada. People wishing to be
involved in various aspects of CHAEN/RCAH should
contact Dr. Tom Bowen, http://tbowen@pol.net.
Canadian HAE comprehensive care clinics
CHAEN/RCAH has collaborated with the Network of
Rare Blood Disorder Organizations (NRBDO; http://
www.hemophilia.ca/en/about-the-chs/collaboration/net-
work-of-rare-blood-disorder-organizations/) to propose
comprehensive care clinics across Canada for the
treatment of various rare blood disorders including
HAE. CHAEN/RCAH and the proposed comprehensive
cares clinics for Canadian HAE care and home therapy
are modeled after the Canadian Hemophilia Clinic
Directors Group model http://www.ahcdc.ca/. The pro-
posal for comprehensive care clinic makeup for Cana-
dian HAE clinics is enclosed in Appendix 1. Home
therapy/self-treatment has been the standard in Hemo-
philia Care since Dr. Hanna Strawczynski and the group
at Montreal Children’s Hospital published their experi-
ence in 1973 [9].
HAE diagnosis
Diagnosis of HAE should be confirmed in laboratory
centres regularly performing investigations into angioe-
dema patients and able to perform C1-INH functional
levels http://www.haecanada.com/files/DiagnosticLabs-
Contacts.dochttp://www.haecanada.com/files/Diagnosti-
cLabTable.doc. The diagnostic approach to angioedema
without urticaria was reviewed by Zingale et al [4] and
the diagnostic algorithm approach has been reviewed in
previous Canadian Consensus documents and updated
in the latest Canadian 2010 HAE Consensus http://
www.haecanada.com/files/DiagnosticAlgorithm100527.
pdf; (see Figure 1); [8]. Careful sample handling is essen-
tial to ensure accurate C1-INH functional results http://
www.haecanada.com/files/DiagnosticSampleHandling.
doc.
HAE patients with confirmed diagnosis are encour-





In Canada, prophylaxis of angioedema events follows the
Canadian and International Consensus Guidelines using
tranexamic acid, anabolic steroids or C1 inhibitor repla-




In Canada, blood products are provided without charge
to the patient and are funded through an interprovin-
cial-territorial funded government program. There is a
central distribution system through Canadian Blood Ser-
vices for nine of the ten provinces and three Territories
or through Hema-Quebec in Quebec so national statis-
tics are available for fractionation blood products. Non-
blood products used in HAE are harder to track
depending on how the product is distributed. Intrave-
nous C1 inhibitor replacement therapy (C1INHRP, Beri-
nert®, CSL Behring) has been licensed for use in Canada
in 2010. Icatibant (Firazyr®, Shire Pharmaceuticals),
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(Rhucin®, Pharming Group NV) have been on clinical
trial in Canada. C1INHRP has been licensed in the Uni-
ted States (Cinryze®, ViroPharma Incorporated, licensed
for prophylaxis of angioedema events; Berinert®,C S L
Behring, licensed for therapy of angioedema events).
Ecallantide (Kalbitor®, Dyax) has been licensed in the
United States for therapy of angioedema events. Icati-
bant (Firazyr®, Shire Pharmaceuticals) has been licensed
in Europe for therapy of angioedema events.
Figure 1 Hereditary Angioedema - HAE - Diagnostic Algorithm.
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under investigation for therapy of angioedema events on
both sides of the Atlantic. We support the treatment
algorithm proposed in the 2010 International Consensus
Algorithm for the Diagnosis, Therapy and Management
of Hereditary Angioedema http://www.haecanada.com/
files/TreatmentChart100527.pdf;(see Figure 3);[8].
In Canada, the use of C1INHRP has been escalating
and we currently transfuse 4.87 millions units of
C1INHRP per annum for the fiscal year 2009/2010 (see
Figure 4) (data supplied by Dr. Francine Decary from
Hema-Quebec and Keith Buchanan from Canadian
Blood Services). For the fiscal year 2009/2010, 1,712,500
units were infused in Quebec (population 7,828,900;
219,000 units per million population per annum);
3,160,000 units were infused in the rest of Canada
(population 25,911,000; 122,000 units per million popu-
lation per annum); 144,000 units infused per million
population per annum for Canada total. Like other
reports, we estimate an incidence of 1:10,000 to 1:50,000
HAE patients - 20 to 100 HAE patients per million
population. Statistics Canada estimates the 2010 Cana-
dian population at approximately 33,739,900 which
would predict 675 to 3374 HAE patients in Canada. If
one assumes an average infusion of 1000 units
C1INHRP (two vials of 500 units each vial), this trans-
lates to a current utilization of 1.4 to 7.2 infusions of
C1INHRP per patient per year (includes infusions in
acquired C1INH deficiency meaning these are likely
high estimates per HAE patient). This has increased
Figure 2 Hereditary Angioedema - HAE - Prophylaxis Algorithm.
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between 0.3 and 1.7 infusions per HAE patient per year
[6]. Without an active national patient registry and with-
out an active replacement product tracking system,
these data remain guesses and are not accurate. We pro-
pose instituting a national data base registry for HAE
patients and a national tracking system for replacement
product utilization for HAE in Canada again modeled
after the Hemophilia Care Program in Canada. Dr.
Bruce Ritchie is undertaking rewriting of the
Hemophilia Program blood product tracking program
(Canadian Hemophilia Assessment and Resource Man-
agement System, CHARMS) and will hopefully include
C1INHRP and other HAE treatment product tracking.
This utilization is approaching the previously reported
figures from Drs. Cicardi and Zingale from their clinic
in Milan where their patients received an average of
3.85 infusions per year for laryngeal edema, 7.93 infu-
sions per year for abdominal edema, and 1.57 infusions
per year for cutaneous edema [10]. We speculate that
the increased utilization is due to improved diagnosis,
increased patient awareness of prophylaxis and treat-
ment options, and increased physician awareness of the
diagnosis and management of this disorder. We hope
that the several national and international conferences
hosted in Canada in conjunction with the Canadian
Hematology Society and the Canadian Society of Allergy
and Clinical Immunology have brought this about rais-
ing the standard of care closer to that of many European
Countries and showing utilization figures now approach-
ing those of European countries with mature HAE man-
agement programs in place and where Berinert® has
been available for therapy for about 25 years.
Home therapy
Again modeling the Hemophilia Home Care program,
some HAE patients receive home care self or assisted
administration on demand. Example of self or assisted
administration may be found on the CHAEN/RCAH
Figure 3 Treatment of Acute Hereditary Angioedema - HAE - Attacks.
Figure 4 Canadian C1-Inhibitor Replacement (C1INHRP)
Therapy.
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1). Other home therapy information and standards of
care are reviewed by Dr. Hilary Longhurst [11,12]. In
centres where home therapy has not yet been insti-
tuted, implementation of such HAE home therapy can
be most rapidly accomplished by partnering with the
local Hemophilia Home Care Clinic. We hope Com-
prehensive Care Clinics for HAE and other rare blood
disorders will become established across Canada in
parallel and partnership with Hemophilia clinics and
Rare Blood Disorder clinics across Canada. Patients
with rare disorders such as blood disorders receive
optimum care through such Comprehensive Care
C l i n i c sa n dt e a m ss p e c i a l i z e di nm a n a g e m e n to fs u c h
complex disorders.
Some CHAEN/RCAH Physicians and clinics interested
in HAE are listed on the CHAEN/RCAH website: http://
www.haecanada.com/files/ChaenClinics.doc.
Summary
We believe management of HAE in Canada has improved
over the past decade thanks to the efforts of first the
Canadian Hereditary Angioedema Society (CHAES)/Soci-
été d’angioédème héréditaire du Canada (SAHC) and
then the Canadian Hereditary Angioedema Network
(CHAEN)/Réseau Canadien d’Angioédème Héréditaire
(RCAH) http://www.haecanada.com. CHAEN/RCAH has
a patient advisory group that has evolved from the origi-
nal CHAES/SAHC and it is hoped that the HAE Patient
Group will again formally organize and replace the cur-
rent patient advisory committee of CHAEN/RCAH (this
is being worked on by Barbara Mako, current Patient
Advisory Group Chair). Clinical research in diagnosis,
therapy, and management continues in HAE clinics in
Canada and it hoped more clinics will join CHAEN/
RCAH and become involved in such clinical research.
Comprehensive Care Clinics for HAE are slowly develop-
ing and we hope these will continue to evolve and colla-
borate with the National Rare Blood Disorders
Organization (NRBDO) and the NRBDO clinics evolving
there. Until new therapeutic products become licensed in
Canada, use of these is under clinical trial studies or
available through Health Canada Special Access Program.
We are excited that the first licensing of a therapeutic
product has finally occurred in 2010 (Berinert®)a n d
anxiously wait licensing of other therapeutic options for
HAE patients. CHAEN/RCAH members will remain
involved in the ongoing development of international
consensus approach and evidence based guidelines for
HAE management.
We should remember: “It can be done - It must be
done for the sake of our patients” (Tom Bowen).
Appendix 1
Comprehensive Care Clinics for Hereditary Angioe-
dema - 2010 05 27
(Modified by permission from: http://www.haeca-
nada.com - comprehensive care clinics)
Comprehensive Patient Care Clinics: Clinical care,
Education, and Research
Comprehensive care for HAE is based on the recogni-
tion that HAE is a chronic disease and care is complex,
requiring a highly specialized and multidisciplinary
approach. A comprehensive care clinic must provide
accountability for in-hospital and home use of expensive
and potentially toxic treatments, track outcomes (both
beneficial and adverse), and develop and meet Standards
of Care for HAE.
Comprehensive HAE Clinics will Provide:
1 Best Clinical Treatment outcomes including:
a. a comprehensive care team made up of nurse
coordinator, clinician, social worker, data man-
ager, pain management specialist, genetic coun-
selor, and administrative support;
b. access to specialized diagnostic testing;
c. access to home treatment;
d. a networked Patient Information System to
facilitate product recalls - collect data on therapy
outcome measures and safety, and facilitate parti-
cipation in clinical trials
e. access to clinical advances as they become
available;
f. access to 24 hour support;
g. access to up-to-date standards of care, includ-
ing standardized wallet cards;
h. tracking and intermittent audit of quality out-
comes including beneficial and adverse outcomes
through secure, comprehensive and networked
data management.
2 Education of patients and staff regarding:
a. responsible Self/Family Care (home care
model) with home and self infusion/administra-
tion instruction and support;
b. developments in the cause, diagnosis, treat-
ment, outcomes, and prognosis of HAE
c. changes in the administrative management of
the clinic
3 An environment conducive to research including:
a. access to and support for clinical trials of new
treatments;
b. access to and support for translational
research in diagnosis and prognosis;
c. access to and support for psychosocial
research such as quality of life studies.
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